Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Wojciech Jurczak"'
Autor:
Michael L, Wang, Wojciech, Jurczak, Mats, Jerkeman, Judith, Trotman, Pier L, Zinzani, David, Belada, Carola, Boccomini, Ian W, Flinn, Pratyush, Giri, Andre, Goy, Paul A, Hamlin, Olivier, Hermine, José-Ángel, Hernández-Rivas, Xiaonan, Hong, Seok Jin, Kim, David, Lewis, Yuko, Mishima, Muhit, Özcan, Guilherme F, Perini, Christopher, Pocock, Yuqin, Song, Stephen E, Spurgeon, John M, Storring, Jan, Walewski, Jun, Zhu, Rui, Qin, Todd, Henninger, Sanjay, Deshpande, Angela, Howes, Steven, Le Gouill, Martin, Dreyling, Joseph C, Gardiner
Publikováno v:
New England Journal of Medicine. 386:2482-2494
Ibrutinib, a Bruton's tyrosine kinase inhibitor, may have clinical benefit when administered in combination with bendamustine and rituximab and followed by rituximab maintenance therapy in older patients with untreated mantle-cell lymphoma.We randoml
Autor:
Frederic Peyrade, Graham P. Collins, Yihua Lee, Jutta K. Neuenburg, Michael Wang, Robert T. Chen, Geoffrey Chong, Karl Eckert, Constantine S. Tam, Radhakrishnan Ramchandren, Lionel Karlin, Ka Lung Wu, Mark Bishton, Paul Eliadis, Wojciech Jurczak
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-8 (2021)
Journal of Hematology & Oncology
Journal of Hematology & Oncology
Ibrutinib plus venetoclax, given with an ibrutinib lead-in, has shown encouraging clinical activity in early phase studies in mantle cell lymphoma (MCL). The ongoing phase 3 SYMPATICO study evaluates the safety and efficacy of concurrently administer
Autor:
Gandhi Damaj, Deyaa Adib, Sarit Assouline, Michael Dickinson, John Radford, Gilles Salles, Anna Schmitt, Wojciech Jurczak, Jay Yang, Tycel Phillips, Franck Morschhauser, Maciej Kazmierczak, Aristeidis Chaidos, Phillip L. Campbell, Connie Lee Batlevi, Pamela McKay, Hervé Tilly, Stephen Opat, Vincent Ribrag, Jennifer Whalen, Shefali Agarwal
Publikováno v:
Lancet Oncol
Summary Background Activating mutations of EZH2, an epigenetic regulator, are present in approximately 20% of patients with follicular lymphoma. We investigated the activity and safety of tazemetostat, a first-in-class, oral EZH2 inhibitor, in patien
Autor:
Polina Kaplan, Javier de la Serna, Malgorzata Wach, Sean Dolan, Phillip L. Campbell, Jae Hoon Lee, Martin Simkovic, Árpád Illés, Iryna Kraychok, Eric J. Avery, Wojciech Jurczak, Andrzej Pluta, Abraham Jacob, Tomas Kozak, Gerardo Musuraca, Daniel Lysák, Wei Liang, Priti Patel, Cheng Quah, Paolo Ghia
Publikováno v:
Journal of Clinical Oncology. 38:2849-2861
PURPOSE Acalabrutinib, a highly selective, potent, Bruton tyrosine kinase inhibitor, was evaluated in this global, multicenter, randomized, open-label, phase III study in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). MET
Autor:
Marek Dudziński, Monika Długosz-Danecka, Małgorzata Wojciechowska, Michal Osowiecki, Elżbieta Iskierka-Jażdżewska, Weronika Piszczek, Jan Maciej Zaucha, Agnieszka Szymczyk, Edyta Subocz, Joanna Drozd-Sokołowska, Anna Waszczuk-Gajda, Beata Kumiega, Krzysztof Giannopoulos, Ryszard Wichary, Marek Hus, Bartosz Pula, Wojciech Jurczak, Tadeusz Robak, Bożena Katarzyna Budziszewska, Janusz Hałka, Wanda Knopinska-Posluszny, Krzysztof Jamroziak, Agnieszka Szeremet, Andrzej Pluta, Daria Zawirska, Paweł Steckiewicz, Jadwiga Hołojda, Ewa Lech-Marańda
Publikováno v:
Anticancer Research. 40:4059-4066
Background/aim To study the long-term clinical efficacy and tolerability of ibrutinib monotherapy in real-world relapsed and refractory chronic lymphocytic leukemia (RR-CLL) patients outside clinical trials. Patients and methods Clinical data of 171
Autor:
Krzysztof Warzocha, Monika Chełstowska, Wojciech Jurczak, Monika Długosz-Danecka, Bartosz Pula, Agata Malenda, Agnieszka Kołkowska-Leśniak, Agnieszka Końska, Ewa Lech-Marańda, Agnieszka Giza
Publikováno v:
European Journal of Haematology. 104:59-66
Background The standard first-line treatment for primary mediastinal B-cell lymphoma (PMBCL) patients is rituximab-based immunochemotherapy; however, this is not due to the result of randomized clinical trials. Aims We retrospectively investigated 53
Autor:
Paula Marlton, Judith Trotman, Wojciech Jurczak, Gavin Cull, Tycel Phillips, Meletios A. Dimopoulos, David Gottlieb, Chenmu Du, Alessandra Tedeschi, Aileen Cohen, Stephen Opat, Roger G. Owen, Constantine S. Tam, Shirley D'Sa, Jianyong Li, Ramón García-Sanz, Wei Xu, Jane Huang, Andrew W. Roberts, Hongjie Zhu, Jun Zhu, Yuqin Song, Meng Ji, Lei Zhou, Javier Munoz, William Novotny, Wai Y. Chan, Lugui Qiu, Haiyi Guo
Publikováno v:
Blood advances. 6(4)
Zanubrutinib is a selective Bruton tyrosine kinase (BTK) inhibitor evaluated in multiple B-cell malignancy studies. We constructed a pooled safety analysis to better understand zanubrutinib-associated treatment-emergent adverse events (TEAEs) and ide
Autor:
Sirpa Leppä, Su-Peng Yeh, Ronit Gurion, Mehmet Turgut, Sriram Balasubramanian, Laurie H. Sehn, Anas Younes, Sen Hong Zhuang, Xiaonan Hong, Pier Luigi Zinzani, Andres Lopez-Hernandez, Shinya Rai, Caterina Patti, S. Martin Shreeve, Wojciech Jurczak, David Belada, Matthew C. Cheung, Olga Samoilova, Cheolwon Suh, Jessica Vermeulen, Louis M. Staudt, Jodi Carey, Catherine Thieblemont, Peter Johnson, C.S. Chiattone, Ulrich Dührsen, Grace Liu, Wyndham H. Wilson, Steven Sun, Jun Zhu
Publikováno v:
Journal of Clinical Oncology. 37:1285-1295
60th Annual Meeting of the American-Society-of-Hematology (ASH) -- DEC 01-04, 2018 -- San Diego, CA Jurczak, Wojciech/0000-0003-1879-8084; Johnson, Peter/0000-0003-2306-4974; ZINZANI, PIER LUIGI/0000-0002-2112-2651; Leppa, Sirpa/0000-0002-8265-511X W
Autor:
Aryan Hamed, Güray Saydam, Muhit Ozcan, Aruna Mehra, Klaus Geissler, Florian Hiemeyer, Yuankai Shi, Toshiki Uchida, Árpád Szomor, Rinat Galiulin, Lidia Mongay Soler, Fangfang Lv, Eduardo Yanez, Igor Bondarenko, Katya Sapunarova, Matthew J. Matasar, Marcelo Capra, Anjun Cao, Jifeng Feng, Pier Luigi Zinzani, Mihaela Lazaroiu, Krimo Bouabdallah, Jie Jin, Wei Li, Qingyuan Zhang, Wojciech Jurczak, T. Lin, Barrett H. Childs, Ming-Chung Wang, Ross Baker
Publikováno v:
The Lancet. Oncology. 22(5)
Background Copanlisib, an intravenous pan-class I PI3K inhibitor, showed efficacy and safety as monotherapy in patients with relapsed or refractory indolent non-Hodgkin lymphoma who had received at least two therapies. The CHRONOS-3 study aimed to as
Autor:
Raquel Izumi, Ahmed Hamdy, Wayne Rothbaum, Susan O'Brien, Paolo Ghia, Peter Hillmen, Kara Higgins, Richard R. Furman, Tadeusz Robak, Wojciech Jurczak, José A. García-Marco, Arnon P. Kater, Priti Patel, Stephan Stilgenbauer, Mustafa Nuri Yenerel, John C. Byrd, Asher Chanan-Khan, Neil E. Kay, Javier Pinilla-Ibarz, Árpád Illés, Anthony R. Mato, John F. Seymour, Sophia Sohoni, Stéphane Leprêtre
Publikováno v:
Journal of clinical oncology, 39(31), 3441-3452. American Society of Clinical Oncology
J Clin Oncol
J Clin Oncol
PURPOSE Among Bruton's tyrosine kinase inhibitors, acalabrutinib has greater selectivity than ibrutinib, which we hypothesized would improve continuous therapy tolerability. We conducted an open-label, randomized, noninferiority, phase III trial comp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f6a2d584eece7d575bd2a5951f783fb
https://ruj.uj.edu.pl/xmlui/handle/item/290438
https://ruj.uj.edu.pl/xmlui/handle/item/290438